Ipragliflozin is primarily used in the treatment of type 2 diabetes mellitus. It works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps to lower blood glucose levels by promoting the excretion of glucose through urine. This mechanism of action makes it particularly effective in managing hyperglycemia in diabetic patients. Additionally, ipragliflozin has been shown to contribute to weight loss and reduction in blood pressure, which are beneficial for patients with diabetes who often struggle with obesity and hypertension. It is often prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and other medications. The drug is generally well-tolerated, but patients should be monitored for potential side effects such as urinary tract infections and volume depletion.